Chemotherapy of human African trypanosomiasis: current and future prospects

Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable toxicity, poor efficacy, undesirable route of administration, and...

Full description

Saved in:
Bibliographic Details
Published inTrends in parasitology Vol. 19; no. 11; pp. 488 - 494
Main Author Fairlamb, Alan H.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.11.2003
Subjects
African trypanosomiasis
Animals
Drug Resistance
Humans
Parasitic Sensitivity Tests
Treatment Outcome
Trypanocidal Agents - pharmacology
Trypanocidal Agents - therapeutic use
Trypanosoma
Trypanosoma brucei gambiense - drug effects
Trypanosomiasis, African - drug therapy
Online AccessGet full text

Cover

More Information
Summary:Three of the four currently approved drugs for the treatment of African trypanosomiasis (sleeping sickness) were developed over 50 years ago. All of the current therapies are unsatisfactory for various reasons, including unacceptable toxicity, poor efficacy, undesirable route of administration, and drug resistance. The possible modes of action of these drugs are briefly reviewed, as are the possible mechanisms of resistance. The intermediate and long-term prospects for the development of safer, effective drugs are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1471-4922
1471-5007
DOI:10.1016/j.pt.2003.09.002